Study Testing Moderna Vaccine in Prevention of Transmission to Include Young Adults
June 22 (Reuters) – U.S. scientists are expanding a government-funded study that aims to directly answer the question of whether Moderna Inc’s (MRNA.O) COVID-19 vaccine is slowing the spread of SARS-CoV-2.
The study, supported by the National Institutes of Health (NIH), was launched in March to determine whether Moderna’s vaccine can prevent coronavirus infection, limit the amount of virus in the nose, and reduce transmission from people vaccinated to their close contacts. Read more
It was originally designed to be tested in students – some of whom would receive the vaccine on a delayed basis – but will now be expanded to adults between the ages of 18 and 29, including those who choose not to receive a vaccine, the COVID-19 Prevention Network, which oversees COVID-19 vaccine trials in the United States, said Tuesday.
“If our study shows that a COVID-19 vaccine works to prevent infection and transmission of the virus, many more people could decide to be vaccinated, which has huge public health implications,” said Dr. Larry Corey, vaccine expert at Fred Hutchinson Cancer Center in Seattle, and principal investigator of network operations.
In total, the trial will include approximately 18,000 young adults.
Approximately 6,000 participants will be vaccinated upon enrollment, while another 6,000 will receive the vaccine four months later. The remaining 6,000 young adults will be those who choose not to be vaccinated.
More than 40 sites, including universities, health care centers, and community organizations across the United States, will participate in the expanded study.
Report by Mrinalika Roy in Bengaluru; edited by Julie Steenhuysen in Chicago
Our Standards: Thomson Reuters Trust Principles.